CD274 and urinary bladder carcinoma: Since immune checkpoint inhibitors (ICI) have been recently approved for treatment of advanced bladder cancers with the necessity of PD-L1 “positivity” in a first-line setting, analysis of PD-L1 expression in glandular bladder cancer might reveal a treatment option for these rare subtypes.